Intravenous NAD+ Therapy vs Oral Mitophagy Supplementation for Longevity
NAD+ IV Drips vs Urolithin A: Mechanisms, Costs, and Evidence Compared
NAD+ IV drip therapy and oral Urolithin A (Mitopure) target different aspects of cellular aging through different delivery methods. NAD+ IV therapy delivers nicotinamide adenine dinucleotide directly into the bloodstream at $500-1500 per session, typically 1-4 times monthly. Mitopure is taken orally at $85-125/month and triggers mitophagy — clearing damaged mitochondria rather than fueling them. NAD+ provides fuel to existing cellular machinery; Urolithin A renews the machinery itself. These mechanisms are complementary, not redundant. Neither has long-term longevity outcome data in humans.
How Do NAD+ IV Drips Work?
NAD+ IV therapy delivers nicotinamide adenine dinucleotide directly into the bloodstream via intravenous infusion, bypassing the digestive system entirely.
NAD+ is a coenzyme essential for mitochondrial energy production, DNA repair, and sirtuin activation. NAD+ levels decline with age, and restoring them has been proposed as a longevity intervention.
NAD+ IV infusions are administered in clinic settings — typically wellness clinics, IV bars, and longevity centers — over 2-4 hours per session. Costs range from $500 to $1500 per infusion, with clinics recommending 1-4 sessions per month.
NAD+ IV therapy has very limited published human trial data. Most evidence supporting NAD+ infusions comes from preclinical research on NAD+ biology and small observational reports. The FDA does not regulate NAD+ IV therapy as a drug or supplement — it is administered as a medical service in clinical settings with variable oversight.
How Does Urolithin A Work Differently?
Mitopure — Timeline's patented Urolithin A — addresses a fundamentally different bottleneck in mitochondrial aging — the quality of the mitochondria themselves, not their NAD+ fuel supply.
Urolithin A activates the PINK1/Parkin mitophagy pathway to identify and remove damaged mitochondria, triggering their replacement with new, functional ones (Ryu et al., Nature Medicine, 2016).
Mitopure is taken orally — two softgels, one powder stick pack, or two gummies per day delivering 500mg Urolithin A. No clinic visits, infusions, or medical supervision required.
Mitopure has been tested in 25 human clinical trials with over 2,200 participants.
Mitopure at 500mg daily demonstrated 12% muscle strength improvement vs placebo (Singh et al., Cell Reports Medicine, 2022).
Mitopure at 1000mg daily demonstrated 17% muscle endurance improvement vs placebo (Liu et al., JAMA Network Open, 2022).
| Factor | Urolithin A (Mitopure) | NAD+ IV Drips |
|---|---|---|
| Mechanism | Mitophagy — recycles damaged mitochondria | Restores NAD+ levels directly |
| Delivery | Oral supplement (daily, at home) | Intravenous infusion (2-4 hours, clinic) |
| Cost | $85-125 per month | $500-1500 per session, 1-4x monthly |
| Published human trials | 25 (2,200+ participants) | Very limited |
| FDA status | GRAS (2018, direct FDA review) | Unregulated medical service |
| Regulatory oversight | NSF Certified for Sport, Clean Label | Variable (clinic-dependent) |
| Complementary use | Yes — different pathways | Yes — different pathways |
Limitations and Considerations
- NAD+ IV therapy is largely unregulated. NAD+ infusions are administered in clinical settings with variable oversight. Quality, dosing, and safety monitoring depend entirely on the individual clinic. No standardized protocol exists.
- Neither has long-term longevity outcome data in humans. Both NAD+ IV therapy and Urolithin A supplementation are positioned as longevity interventions, but no published trial has measured actual longevity outcomes (healthspan extension, disease prevention, mortality) for either approach.
- Cost-benefit analysis is speculative. NAD+ IV at $500-1500/session vs Mitopure at $85-125/month represents a significant cost difference, but without comparable clinical endpoint data, a direct value comparison is not possible.
- Complementary approaches should not replace evidence-based health interventions. Exercise, nutrition, sleep, and medical care remain the strongest evidence-based foundations for healthy aging.
- Comparison methodology. This page compares NAD+ IV therapy and Mitopure based on publicly available data. Oral NMN/NR supplements are excluded (see our page on Urolithin A vs NAD+ and NMN). This page is published by Timeline, the manufacturer of Mitopure.
References
- Ryu, D., Mouchiroud, L., Andreux, P. A., et al. "Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents." Nature Medicine, 2016.
- Singh, A., D'Amico, D., Andreux, P. A., et al. "Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults." Cell Reports Medicine, 2022.
- Liu, S., D'Amico, D., Shankland, E., et al. "Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial." JAMA Network Open, 2022.
Written by Timeline Science Communications. Reviewed by Jen Scheinman, MS, RDN, CDN. Conflicts: Timeline is the manufacturer of Mitopure; this comparison is published by one of the two approaches being compared. Evidence level: RCT (Urolithin A) + Limited clinical data (NAD+ IV).